Daraxonrasib demonstrates initial antitumor activity in RAS-mutant lung cancer
Daraxonrasib is a RAS inhibitor from Revolution Medicines that has been approved by the Food & Drug Administration for previously treated pancreatic cancer
This Phase 1/2 trial is the first-in-human study of daraxonrasib in patients with non-small cell lung cancer
RAS mutations are the most common cancer drivers of non-small cell lung cancer, occurring in about 30% of patients
The results of this trial initiated the Phase 3 RASolve...
Immune signals may help explain, predict responses to therapies for difficult-to-treat depression
Treatment-resistant depression occurs when symptoms persist after multiple antidepressant treatments
Rapid-acting antidepressants, such as ketamine...
New study identifies genetic markers that could guide emerging prostate cancer treatments
Ferroptosis is a type of cell death that has emerged as a promising avenue to target cancers that are resistant to current therapies
This study...
AI-guided pathology analysis can help predict immunotherapy response in rare cancers
Study utilized AI tool to measure baseline and dynamic changes in the tumor microenvironment and tumor content as patients started immunotherapy treatment
Results demonstrate how AI can uncover biomarkers hidden within the tumor and surrounding microenvironment to determine how likely patients were to benefit over time
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that an artificial intelligence (AI...
Copper-induced cell death activates immune system, may help overcome immunotherapy resistance
Study identifies a new link between immune cells and a copper-induced form of cell death called cuproptosis
Findings suggest a potential strategy...
AI-powered atlas reveals new insights into tertiary lymphoid structures as prognostic and response biomarkers in cancer
New spatial atlas of immune cell structures, called tertiary lymphoid structures (TLSs), reveals how key features vary across...
Tumor microenvironment features may predict immunotherapy response in rare cancers
Phase 2 trial investigated the effectiveness of pembrolizumab (Keytruda) in rare cancers
Overall responses were modest, but analysis showed...
ESTRO: ctDNA improves treatment monitoring for patients receiving metastasis-directed therapy
Analysis from the Phase 2 EXTEND trial showed ctDNA testing provided new insights into treatment response for patients receiving metastasis-directed...
ESTRO: Select breast cancer patients may be able to omit surgery following ablative radiation
Patients in this trial eligible to avoid surgery had a disease control rate of 100% at a median follow-up of over three years ...
RAS inhibitor daraxonrasib demonstrates initial anti-tumor activity in pancreatic cancer
Daraxonrasib is an oral, multi-selective RAS inhibitor from Revolution Medicines
Data from this trial previously prompted the Food and Drug...
AACR: New platform uses machine learning to predict responses in patients with lung cancer
Path-IO is a machine learning platform that incorporates pathology data to predict how patients with non-small cell lung cancer will respond...
AACR: Zedoresertib and lunresertib combination shows promising antitumor activity
Phase I trial provides early clinical proof-of-concept supporting the combination of zedoresertib and lunresertib in certain advanced solid...
AACR: Clinical trial presentations feature advances across cancer care
Early results for first-in-human and first-in-class therapies including an integrin inhibitor and a genetically engineered tumor infiltrating...
First-line targeted therapy shows antitumor activity in patients with advanced lung cancer
First-line zongertinib showed antitumor activity in treatment-naïve patients with advanced or metastatic HER2-mutant ...
Study identifies strategy to overcome radiation therapy resistance in lung cancer
These results show how mitochondrial enzyme dihydroorotate dehydrogenase contributes to radiation therapy resistance
Researchers were able to...
Radiation therapy improves outcomes for 'supermassive’ bile duct tumors
Patient outcomes were significantly better when treated with radiation therapy plus standard-of-care chemotherapy
First-in-class radio-theranostic utilizes novel antibody developed at UT MD Anderson
Study details the development of a novel antibody that targets a specific type of B7-H3, a protein overexpressed in many cancers
Study shows strong evidence for effectiveness of metastasis-directed radiation therapy in prostate cancer
Metastasis-directed therapy (MDT) significantly improved progression-free survival and later endpoints
Data indicate statistically significant...
Study reveals synergistic effect of CDK2 and CDK4/6 combination therapy
This preclinical study explains the mechanism underlying CDK2 and CDK4/6 combination therapy, providing a blueprint for future clinical use...
Engineered nanobodies improved respiratory defenses in preclinical study
There are no current therapies designed to improve protection against multiple different respiratory viruses
Engineered nanobodies improved...
Novel immunotherapy demonstrates early potential to overcome resistance to immune checkpoint therapy
Linavonkibart, also known as SRK-181, is an experimental therapy from Scholar Rock that aims to prevent or overcome resistance to immune checkpoint...
Researchers identify Rb1 as a predictive biomarker for a new therapeutic strategy in some breast cancers
Preclinical study identifies Rb1 deficiency as key therapeutic vulnerability in a subset of breast cancers resistant to standard CDK4/6 inhibitors...
Proton therapy shows survival benefit in Phase III trial for patients with head and neck cancers
At five years, 90.9% of proton patients were alive compared to 81% with traditional radiation
Proton therapy also showed benefits in quality...
ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma
VT3989 is a first-in-class YAP-TEAD inhibitor from Vivace Therapeutics that is currently in Phase I/II trials for patients with advanced solid...
ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy
Cancer patients who received mRNA COVID vaccines within 100 days of starting immunotherapy were twice as likely to be alive three years after...
New computational method improves ability to detect precancerous tissues
CoCo-ST is a novel method of mapping tissues that is superior to current state-of-the-art benchmarks in preclinical models
Technique allows...
ASTRO 2025: At 10 years, SBRT comparable to surgery for early-stage lung cancer
Study is the first to compare 10-year outcomes from surgery and a specific kind of radiation therapy known as SBRT (also called SABR) in non-small...
MD Anderson experts highlight top trends ahead of 2025 ASTRO meeting
Major themes include advances in actionable biomarkers in pancreatic cancer, proton therapy, artificial intelligence and theranostics
MD Anderson...
Researchers identify new approach to overcome resistance to KRAS-targeted therapies
Many cancers with KRAS mutations, the most commonly mutated oncogene, develop rapid resistance to targeted therapy with KRAS inhibitors. A...
Machine learning model improves treatment selection in non-small cell lung cancer
A significant challenge in developing treatment plans for patients with metastatic non-small cell lung cancer (NSCLC) is deciding whether...